TrialHaematologica2019
A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.
Marie Sébert et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
30 papers cite it
this papertrialcites it